MRC RT01: an important trial

Lancet Oncology

Volumn 8, Issue 6, 2007, Pages 459-460

  Denham, James W ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

BIOCHEMISTRY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CLINICAL TRIAL; FOLLOW UP; HUMAN; LETTER; MALE; METASTASIS INHIBITION; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; RADIATION DOSE; RECTUM DISEASE; RECURRENCE RISK; RISK REDUCTION; SAMPLE SIZE; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR LOCALIZATION;

ANDROGEN ANTAGONISTS; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE;

EID: 34249752155     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70152-3     Document Type: Letter

References (10)

1. Dearnaley D., Sydes M., Graham J., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8 (2007) 475-487
2. Collette L., Burzykowski T., and Schroder F. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer 42 (2006) 1344-1350
3. Vicini F., Vargas C., Abner A., Kestin L., Horowitz E., and Martinez A. Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. J Urol 173 (2005) 1456-1462
4. Roach III M., Hanks G., Thames J., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
5. Studer U., Whelan P., Albrecht W., et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 24 (2006) 1868-1876
6. Pollack A., Zagars G., Starkschall G., et al. Prostate cancer radiation dose response: results of the MD Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
7. Zietman A., DeSilvio M., Slater J., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. A randomized controlled trial. JAMA 294 (2005) 1233-1239
8. Peeters S., Heemsbergen W., Koper P., et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
9. Christie D., Denham J., Steigler A., et al. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation. Radiother Oncol 77 (2005) 117-125
10. Lancar R., Kramar A., and Haie-Meder C. Non-parametric methods for analysing recurrent complications of varying severity. Stat Med 14 (1995) 2701-2712